No Data
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.
Sector Update: Health Care Stocks Fall Premarket Monday
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,250
Does Eli Lilly (NYSE:LLY) Deserve A Spot On Your Watchlist?
Express News | Resmed Shares Down 5.2% Premarket After U.S. FDA Approves Lilly's Weight-Loss Drug for Sleep Apnea
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark